Mabwell Bioscience Forecasts Net Loss of RMB 900–995 Million for 2025 Amid Revenue Growth and Expanded R&D

Gelonghui January 23rdMabwellAnnouncement: It is estimated that the net profit attributable to the parent company's owners for the fiscal year 2025 will continue to incur losses compared with the same period of the previous year. The net profit attributable to the parent company's owners is expected to be a loss of 900 million yuan to 995 million yuan. The net profit attributable to the parent company’s owners after deducting non-recurring gains and losses is expected to be a loss of 905 million yuan to 999 million yuan. In the same period last year, the net profit attributable to the parent company’s owners was a loss of 1.044 billion yuan, and the net profit attributable to the parent company’s owners after deducting non-recurring gains and losses was a loss of 1.07 billion yuan. The company’s operating income has increased significantly compared to the same period last year, mainly due to the large revenue amount recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and Disc Medicine, Inc., as well as a substantial increase in pharmaceutical sales revenue compared to the same period last year.